000			nab a22 7a 4500
999			_c16372 _d16372
003			PC16372
005			20210625062821.0
008			210428b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92463 _aRuiz García, Raquel _eInmunología
100			_92598 _aSerrano, Manuel _eInstituto de Investigación i+12
100			_92597 _aMartinez-Flores, Jose A. _eInstituto de Investigación i+12
100			_91986 _aMora Diaz, Sergio _eInmunología
100			_92825 _aMorillas López, Luis _eReumatología
100			_92316 _aMartín Mola, Mª Ángeles _eHematología y Hemoterapia
100			_9576 _aMorales Cerdán, José María _eNefrología
100			_91510 _aPaz Artal, Estela _eInmunología
100			_9661 _aSerrano Hernández, Antonio _eInmunología
245	0	0	_aIsolated IgA anti- β2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome. _h[artículo]
260			_bJournal of immunology research, _c2014
300			_a2014:704395.
500			_aFormato Vancouver: Ruiz-García R, Serrano M, Martínez-Flores JÁ, Mora S, Morillas L, Martín-Mola MÁ et al. Isolated IgA anti- β2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome. J Immunol Res. 2014;2014:704395.
501			_aPMID: 24741618 PMC3987939
504			_aContiene 38 referencias
520			_aSeronegative antiphospholipid syndrome (SNAPS) is an autoimmune disease present in patients with clinical manifestations highly suggestive of Antiphospholipid Syndrome (APS) but with persistently negative consensus antiphospholipid antibodies (a-PL). IgA anti-β 2 Glycoprotein I (aB2-GPI) antibodies are associated with APS. However, they are not currently considered to be laboratory criteria due to the heterogeneity of published works and the use of poor standardized diagnostic systems. We have aimed to assess aPL antibodies in a group of patients with clinical manifestations of APS (C-APS) to evaluate the importance of the presence of IgA aB2GPI antibodies in APS and its relation with other aPL antibodies. Only 14% of patients with C-APS were positive for any consensus antibody, whereas the presence of isolated IgA aB2GPI antibodies was found in 22% of C-APS patients. In patients with arterial thrombosis IgA aB2GPI, antibodies were the only aPL antibodies present. Serologic profile in primary APS (PAPS) is different from systemic autoimmune disorders associated APS (SAD-APS). IgA aB2GPI antibodies are more prevalent in PAPS and IgG aB2GPI antibodies are predominant in SAD-APS. The analysis of IgA aB2GPI antibodies in patients with clinical manifestations of PAPS might avoid underdiagnosed patients and provide a better diagnosis in patients with SAD-APS. Laboratory consensus criteria might consider including analysis of IgA aB2GPI for APS diagnosis.
710			_9625 _aInstituto de Investigación imas12
710			_9395 _aServicio de Inmunología
710			_986 _aServicio de Nefrología
710			_9123 _aServicio de Reumatología
710			_9297 _aServicio de Hematología y Hemoterapia
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987939/pdf/JIR2014-704395.pdf _yAcceso libre
942			_2ddc _cART _n0